Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, May 1998, p. 1239-1244, Vol. 42, No. 5
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Killing of Chlamydia trachomatis by
Novel Antimicrobial Lipids Adapted from Compounds in Human Breast
Milk
M. F.
Lampe,1,*
L. M.
Ballweber,1
C. E.
Isaacs,2
D. L.
Patton,1 and
W.
E.
Stamm1
University of Washington, Seattle,
Washington,1 and
NYS Institute for Basic
Research, Staten Island, New York2
Received 8 September 1997/Returned for modification 22 December
1997/Accepted 5 March 1998
 |
ABSTRACT |
The development of new methods for prevention of sexually
transmitted Chlamydia trachomatis infection is a top public
health priority. Topical self-administered vaginal microbicides
represent one such approach in which the organism is eradicated at the
time of initial exposure. To this end, we examined the activity of five
synthetic lipids adapted from naturally occurring compounds found in
human breast milk. C. trachomatis serovar D or F elementary bodies were added to serial dilutions of the lipids and incubated for
various times. Aliquots were then cultured in monolayers of McCoy
cells, and inclusions were counted. A 7.5 mM concentration of
2-O-octyl-sn-glycerol completely prevented
growth of C. trachomatis after 120 min of contact with the
organism. The remaining lipids, 1-O-octyl-,
1-O-heptyl-, 2-O-hexyl-, and
1-O-hexyl-sn-glycerol, showed less activity. On
electron microscopic examination, the lipids were shown to have
disrupted the chlamydial inner membrane, allowing leakage of the
cytoplasmic contents from the cell. Lipid activity was unaffected by
the presence of 10% human blood or alterations in pH from 4.0 to 8.0, conditions reflecting those sometimes found in the vagina. Our results
suggest that these lipids, especially
2-O-octyl-sn-glycerol, may be effective as topical microbicides in preventing the transmission of C. trachomatis. Further efficacy and toxicity studies with these
lipids and assessment of their activity against other sexually
transmitted disease pathogens are in progress.
 |
INTRODUCTION |
As many as 12 million individuals in
the United States are infected with sexually transmitted diseases
(STDs) each year, and many of these infections result in serious
reproductive sequelae (3). Since current prevention
strategies have been only partially successful, the use of topical
microbicides offers a new approach to the prevention of STDs that is
particularly attractive in that they are broad spectrum in their
activity and can be self administered by women before sexual contact.
An ideal microbicide would prevent STDs caused by bacterial pathogens
such as Chlamydia trachomatis and Neisseria
gonorrhoeae, as well as those caused by human immunodeficiency virus, human papillomavirus, herpes simplex viruses, and the parasite Trichomonas vaginalis. In addition, such preparations should
be spermicidal but should not disrupt the normal flora or be toxic to
the vaginal epithelium. Since C. trachomatis is the most
common bacterial cause of STDs in the United States (1),
accounting for at least one-third of all these infections, we have
focused our efforts on this pathogen.
Human breast milk contains numerous antimicrobial compounds
(5), some of which are lipid based. We have modified some of these antimicrobial lipids to increase their stability and aqueous solubility while maintaining their antimicrobial activity and then
synthesized these compounds for use in antimicrobial assays. These
novel lipids have been shown to have inhibitory activity against
Escherichia coli, Salmonella enteritidis, and
Staphylococcus epidermidis (4), but their
activity against Chlamydia is unknown. C. trachomatis is transmitted from an infected to an uninfected individual in genital secretions via sexual contact. Even though C. trachomatis is an obligate intracellular bacterium, the
elementary body (EB) or infectious form of the organism is found
extracellularly in secretions. EBs are adapted for survival in
cell-free conditions but are susceptible in vitro to various
antimicrobials such as detergents (7), peptides
(11), whole human milk, and fractions of it (2).
We undertook these studies to examine whether genital strains of
C. trachomatis were killed by these novel antimicrobial lipids adapted from human breast milk. Five lipids, including 1- and
2-O-hexyl-sn-glycerol,
1-O-heptyl-sn-glycerol, and 1- and 2-O-octyl-sn-glycerol, were examined in an in
vitro C. trachomatis viability assay and assessed for their
morphologic effects upon C. trachomatis EBs by electron
microscopy.
 |
MATERIALS AND METHODS |
Cell culture.
Low-passage (<15 passages) McCoy mouse
fibroblast cells (ATCC CRL 1696) were maintained in antibiotic-free
Eagle's minimal essential medium with 10% fetal calf serum (EMEM).
The McCoy cells were checked routinely once per month for mycoplasma
contamination.
Inoculum.
C. trachomatis serovars D (UW-3/Cx) and F
(UW-6/Cx) were grown in McCoy cells in antibiotic-free EMEM, purified
on Renografin gradients, and stored at
70°C in SPG (219 mM sucrose,
3.8 mM KH2PO4, 8.6 mM
Na2HPO4, 4.9 mM glutamic acid [pH 7.0]).
Immediately prior to use, the purified organisms were thawed and
diluted in SPG.
Novel lipids.
Five lipids, including 1- and
2-O-hexyl-sn-glycerol,
1-O-heptyl-sn-glycerol, and 1- and
2-O-octyl-sn-glycerol, were tested. The
structures of these lipids are shown in Fig.
1. The lipids were designed by C. E. Isaacs and synthesized by Deva Biotech (Hatboro, Pa.). Each lipid was
received as a 100× solution in 100% ethyl alcohol (EtOH). The 1- and
2-O-hexyl-sn-glycerol ethers were diluted to an
initial concentration of 15 mM (2.64 mg/ml), and the
1-O-heptyl-sn-glycerol ether and 1- and
2-O-octyl-sn-glycerol ethers were diluted to 50 mM (10.2 mg/ml) in SPG or EMEM. After each dilution, the lipids were
vortexed for 15 to 30 s to ensure their even distribution.
Controls.
Polymyxin B and penicillin G were used as positive
and negative controls, respectively, at an initial concentration of 2 mg/ml in the preinoculation assays. EMEM and EtOH were used as controls in the alamarBlue cell toxicity assay. All controls were prepared fresh
on the day of the assay.
Preinoculation assay.
C. trachomatis serovar D or F
(106 inclusion-forming units [IFU]) in SPG was added to
dilutions of each lipid or positive or negative control antibiotics
(polymyxin B and penicillin G) and incubated for 0, 30, 60, 90, or 120 min. After each time period, a 5-µl aliquot of the organism-drug
mixture was diluted 1:40 in 195 µl of SPG. One hundred microliters of
this dilution was then added to a McCoy cell monolayer in a 96-well
microtiter plate and centrifuged for 1 h to inoculate the tissue
culture cells. The organism-drug mixture was then removed and replaced
with EMEM containing 1 µg of cycloheximide per ml. The cultures were
incubated for 48 h and stained with the Chlamydia
genus-specific fluorescein isothiocyanate-labeled monoclonal antibody
CF2, and the chlamydial inclusions in three fields were counted. All
assays were performed in triplicate, the inclusion counts were
averaged, and the polymyxin B positive control and the penicillin G
negative control were run in parallel. Additional wells were inoculated
either with the C. trachomatis organisms only, which served
as an organism control, or with SPG only, to monitor McCoy cell
morphology. Percent killing in tests with lipid, the polymyxin B
positive control, and the penicillin G negative control were calculated
by the following formula: [(mean IFU of organism control
mean
IFU of test)/(mean IFU of organism control)] × 100. The lowest
concentration of lipid which showed 100% killing was defined as the
minimal cidal concentration (MCC). One hundred percent killing
represents a decrease of at least 104 organisms, from the
original 106 IFU in the inoculum to 160 IFU, the minimum
number of IFU which can be counted in our assay.
alamarBlue cytotoxicity assay.
The preinoculation assay was
duplicated except that no Chlamydia organisms were added.
Lipid dilutions were further diluted 1:40 in EMEM as in the
preinoculation assay and then added to 24-h monolayers of McCoy cells
in 96-well microtiter plates and incubated for 1 h. Lipid
dilutions were aspirated from the wells and replaced with EMEM
containing 1 µg of cycloheximide per ml, and cultures were incubated
for 48 h. alamarBlue (Alamar Biosciences, Inc., Sacramento,
Calif.) was then added to each well, and the cells were incubated for
4 h. alamarBlue is chemically reduced by the metabolic activity of
growing cells, which causes the fluorometric-colorimetric REDOX
indicator to change from an oxidized, nonfluorescent blue form to a
reduced, fluorescent red form. The optical densities of the wells
(OD570 and OD600) were read, and percent
inhibition of McCoy cells was calculated in comparison to that of EMEM
negative controls by the following formula: percent inhibition = [(mean OD570
mean OD600 of negative cell
control)
(mean OD570
mean OD600 of
test)]/[mean OD570
mean OD600 of negative
cell control] × 100 (9).
Preinoculation assay in the presence of 10% human blood.
The preinoculation assay described above was used with the addition of
10% whole human blood. Blood was collected from one of the authors who
was not receiving antibiotics and who has no antichlamydial antibodies,
as measured by microimmunofluorescence (10). The pH of the
lipid dilutions was adjusted to pH 7.0. Assays were performed only at
0- and 120-min time points. Ten percent human blood was also added to
the organism controls.
Preinoculation assay with pH alterations.
The preinoculation
assay described above was followed except that lipid dilutions were
adjusted to pH 4, 5, 6, 7, or 8 with 1 M
Na2HPO4 or 1 M KH2PO4
before C. trachomatis IFU were added. Again, assays were
performed only at 0- and 120-min time points and all controls were
tested at each different pH value.
Electron microscopic examination of C. trachomatis
exposed to lipids.
The lowest concentration of each of the lipids
showing 100% killing in the preinoculation assay was incubated with
C. trachomatis EBs for 90 min. The treated organisms were
pelleted, fixed with 2% glutaraldehyde, postfixed in 1% osmium
tetroxide in deionized water, dehydrated in a series of alcohols,
embedded in EMbed 812 (Electron Microscope Supplies, Chestnut Hill,
Mass.), thin sectioned, stained with uranyl acetate and lead citrate,
and examined in a Philips (Eindhoven, The Netherlands) model CM-10
transmission electron microscope. Organisms exposed to SPG were treated
as described above and examined for typical morphology.
 |
RESULTS |
Comparison of the antichlamydial activities of the five
lipids.
The antichlamydial activities of all five lipids against
C. trachomatis serovar D at 120 min are shown in Fig.
2. It is important to note that the 2- and 1-O-octyl-sn-glycerol derivatives showed 100% killing at lower concentrations (7.5 and 15 mM respectively) whereas the 1-O-heptyl-sn-glycerol and 1- and
2-O-hexyl-sn-glycerol derivatives showed 100%
killing only at higher concentrations (25 to 50 mM). Table
1 summarizes the MCCs of each lipid
against C. trachomatis serovars D and F.

View larger version (102K):
[in this window]
[in a new window]
|
FIG. 2.
Comparison of the antichlamydial activities of the five
novel lipids examined in these studies. The preinoculation assay was
used, and the percent killing of C. trachomatis serovar D
after 120 min of exposure to each lipid or the controls was plotted.
The initial concentrations of polymyxin B and penicillin G were 2,000 µg/ml.
|
|
Determination of lipid cytotoxicity with alamarBlue.
The
preinoculation assay described above includes a 1:40 dilution of the
lipid-organism mixture prior to centrifugation of the inoculum. To
ensure that the diluted lipid contained no residual toxicity for the
McCoy cells used to culture Chlamydia, all dilutions of the
lipids were tested in the alamarBlue cytotoxicity assay. This assay
detects low levels of toxicity resulting in cell changes that are not
microscopically visible. However, none of the dilutions of the lipids
used in the preinoculation assay showed significant cytotoxicity.
Results with 2-O-octyl-sn-glycerol are shown in Table 2. The other lipids showed similar
negative results.
Comparison of lipid activities against C. trachomatis
serovars D and F.
To determine whether these antimicrobial lipids
were active against different serovars of C. trachomatis,
dilutions of all the lipids were tested against both serovars D and F
for various periods of time. Results with
2-O-octyl-sn-glycerol at 0 and 120 min are shown
in Fig. 3 and indicate that it was
equally active against both serovars, with an MCC of 7.5 mM at 120 min
for both organisms. In general, the other lipids showed more killing of serovar F than of serovar D, but both serovars were killed after 120 min. 1-O-Hexyl-sn-glycerol was the exception
because it never completely killed serovar D even after 120 min.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 3.
Comparison of
2-O-octyl-sn-glycerol activity against C. trachomatis serovars D and F. The percent killing of each serovar
after exposure to 2-O-octyl-sn-glycerol for
0 and 120 min in the preinoculation assay is plotted, and standard
deviations from triplicate tests are indicated by error bars. Values
were calculated in comparison to that of the organism-only control as
described in Materials and Methods. Results for the polymyxin B
positive and penicillin G negative controls are also shown.
|
|
Lipid activity in the presence of 10% human blood.
To
directly test whether the activity of these lipids would be reduced in
the presence of human blood found in the vagina during the menstrual
cycle, the preinoculation assay was performed in parallel in the
presence and absence of 10% whole human blood. Figure
4 shows the results comparing
2-O-octyl-sn-glycerol activities against C. trachomatis serovar D with and without 10% human blood after 0 and 120 min of exposure. The MCC with blood (15 mM) was one dilution
higher than that without blood (7.5 mM) after 120 min. Blood,
therefore, has a small but most likely insignificant effect on lipid
antichlamydial activity.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 4.
Percent killing values for C. trachomatis
serovar D exposed to the indicated concentrations of
2-O-octyl-sn-glycerol for 0 and 120 min in the
presence and absence of 10% whole human blood. Error bars indicate
standard deviations. Values for the organism and for polymyxin B and
penicillin G controls were also determined in the preinoculation assay
with and without the addition of 10% whole human blood.
|
|
Lipid activity at pH 4, 5, 6, 7, and 8.
Because the pH can
vary widely in the human vagina, we tested the activity of the lipids
at pH 4, 5, 6, 7, and 8 against C. trachomatis serovar D for
0 and 120 min. As shown in Fig. 5,
2-O-octyl-sn-glycerol at a few pH-concentration
combinations showed increased (pH 8, 3.75 mM) or decreased (pH 6, 7.5 mM) killing of C. trachomatis serovar D when the organism
was exposed to the lipid for 120 min. In general, however, differences
in pH did not have a major impact on
2-O-octyl-sn-glycerol activity (Table
3).

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 5.
2-O-Octyl-sn-glycerol activity at
pH 4, 5, 6, 7, and 8 at 120 min. The percent killing of C. trachomatis serovar D by
2-O-octyl-sn-glycerol is shown at each pH value,
with standard deviations indicated by error bars for each
concentration. Values were calculated in comparison to that of the
organism control at the same pH value. The preinoculation assay
protocol was followed.
|
|
Examination by electron microscopy of C. trachomatis
exposed to lipids.
Chlamydia organisms exposed to the lowest
concentration of each of the lipids that resulted in 100% killing in
the preinoculation assay were examined by transmission electron
microscopy. After incubation with the most active 2- and
1-O-octyl-sn-glycerol derivatives, only C. trachomatis ghosts containing outer membrane shells and no
cytoplasmic contents remained (similar to the organism visible on the
left in Fig. 6B). After incubation with
the less active lipids, 2- and
1-O-hexyl-sn-glycerol derivatives, not only
hollow ghosts but also organisms in the process of leaking their
cytoplasmic contents could be seen (organism visible on the right in
Fig. 6B). In both cases, it appeared that the inner membrane of
Chlamydia was disrupted while most of the outer membrane
remained intact. We did not examine the
1-O-heptyl-sn-glycerol activity by electron microscopy.

View larger version (102K):
[in this window]
[in a new window]
|
FIG. 6.
Transmission electron micrographs of C. trachomatis serovar D treated with
1-O-hexyl-sn-glycerol. (A) C. trachomatis serovar D EBs exposed to SPG only and processed for
microscopy. It is important to note the intact outer membrane
structures and electron-dense cytoplasmic mass. (B) EBs exposed to 50 mM 1-O-hexyl-sn-glycerol for 90 min appear as
hollow ghost-like structures. It is important to note that the inner
membrane has lost its structural integrity.
|
|
 |
DISCUSSION |
The development of a topical microbicide that is safe,
inexpensive, easy to use, and effective against the most common STD pathogens could be of great importance in reducing the transmission of
STDs. The lipids we have examined in these studies may contribute toward achieving this goal. The
2-O-octyl-sn-glycerol lipid was the most active
of the five closely related lipids tested. A 7.5 mM concentration of
this lipid killed C. trachomatis after 90 min of exposure to
the organism. A 15 mM concentration of
1-O-octyl-sn-glycerol also killed C. trachomatis after 30 min of contact. The
1-O-heptyl-sn-glycerol and 1- and
2-O-hexyl-sn-glycerol derivatives were less
active, either requiring higher concentrations or longer exposure times to kill C. trachomatis or showing incomplete killing at the
concentrations and times examined. A 7.5 mM concentration of
2-O-octyl-sn-glycerol can be easily synthesized
and incorporated into a vehicle suitable for self administration and is
currently being formulated. Preliminary studies have shown no vaginal
irritation in the rabbit model by lipid concentrations as high as 120 mM (5a). Since this concentration is well above the minimum
necessary to kill C. trachomatis and can readily be
synthesized, millimolar lipid concentrations are physiologically
relevant for a topical microbicide. A further advantage of such a lipid
preparation is its markedly lower cost in comparison to that of other
antimicrobials such as peptides.
Lipids, which disrupt the lipid bilayers of pathogens, might also
disrupt cell membranes they come into contact with, including the
epithelial cells lining the human vagina. Toxicity of this type caused
by lipids applied to mucosal surfaces would likely be at least partly
prevented by the mucous layer. Under the conditions of our assay
utilizing 1 h of contact of a 1:40 dilution of the lipid
concentrations tested, we found that the lipids were not toxic to McCoy
cells as determined by the alamarBlue test. However, toxicity of these
lipids is an important issue which needs to be examined in future
studies of humans and in animal models.
Since there are numerous different C. trachomatis serovars
which can cause urogenital disease, we wanted to determine whether these antimicrobial lipids were active against different serovars. Of
the lipids tested, none showed significant variability in activity when
two different serovars, D and F, were tested. For example, the same
concentration of 2-O-octyl-sn-glycerol necessary
to kill serovar D (7.5 mM) was also completely active against serovar F. While additional strains and serovars need to be tested, these results suggest that a topical
2-O-octyl-sn-glycerol preparation would likely be
broadly active against many or most of the C. trachomatis
serovars associated with STDs.
In addition to lipids, there are other classes of antimicrobials such
as naturally occurring antimicrobial peptides that could be used as
topical microbicides. One potential problem with defensins and other
antimicrobial peptides is their reduced activity in the presence of
serum (8). During the menstrual period, topically applied
defensins would come in contact with serum proteins contained in
menstrual blood, thus diminishing their activity. The short-chain monoglycerides examined in these studies could bind to proteins such as
albumin or to other proteins with fatty acid binding sites that are
found in blood (4). However, the activity of the lipids examined in these studies was not decreased by the presence of 10%
whole human blood. These results indicate that a topical lipid preparation would likely remain active even during the menstrual period, when other antimicrobial compounds such as defensins might have
reduced activity.
The pH of the human vagina varies greatly, from pH 4 in healthy women
to pH 5 to 6 in women with bacterial vaginosis, pH 7 in women who are
postmenopausal, and pH 8 after semen is deposited. Since the ideal
topical antimicrobial should be effective at all of these different pH
values, we examined the activity of the lipids at pH 4, 5, 6, 7, and 8. There are some changes in the activity of
2-O-octyl-sn-glycerol at pH values other than 7, but these changes are likely not biologically significant. Our results indicate that a topical lipid preparation would be active under a wide
variety of pH conditions in the female genital tract.
Antimicrobial lipids are thought to be active because they disrupt
lipid bilayers. The electron micrographic examination of Chlamydia treated with these lipids confirms the results in
the preinoculation MCC assays. The lipids were observed to disrupt the
chlamydial inner membrane, allowing the cytoplasmic contents to leak
out of the cell and confirming that the lipids are directly active
against the organism. The absence of cellular toxicity observed in the
alamarBlue test is also consistent with the conclusion that the
antichlamydial activity of these lipids results directly from
disruption of the chlamydial membrane and not from toxicity to the
McCoy cells.
In conclusion, these lipids, which are related to the antimicrobial
monoglyceride esters found in human breast milk (6), are
able to kill C. trachomatis directly;
2-O-octyl-sn-glycerol is the most active of those
tested. Further tests to determine whether they are active against
other chlamydial strains and other STD pathogens are under way. Given
further testing of toxicity and efficacy in humans, it is possible that
these lipids would make an effective topical microbicide to kill
sexually transmitted Chlamydia on contact at the time of
sexual transmission, before infection occurs. These naturally occurring
compounds, found in humans at mucosal membranes, are likely to be
relatively nontoxic and may be well suited for this proposed use.
 |
ACKNOWLEDGMENTS |
This work was supported by Public Health Service grants AI-39061
and AI-31448 from the National Institutes of Health.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Medicine, Division of Allergy and Infectious Diseases, Box 356523, University of Washington, Seattle, WA 98195. Phone: (206) 616-4124. Fax: (206) 616-4898. E-mail: lampe{at}u.washington.edu.
 |
REFERENCES |
| 1.
|
Centers for Disease Control.
1997.
Chlamydia trachomatis genital infections United States, 1995.
Morbid. Mortal. Weekly Rep.
46:193-198[Medline].
|
| 2.
|
Elbagir, A.,
M. Petterson,
M. Lindahl,
M. Genc,
G. Froman, and P. A. Mardh.
1990.
Influence of whole human milk, and fractions thereof, on inclusion-formation of Chlamydia trachomatis in McCoy cells.
APMIS
98:609-614[Medline].
|
| 3.
|
Institute of Medicine.
1996.
The hidden epidemic: confronting sexually transmitted diseases.
National Academy Press, Washington, D.C.
|
| 4.
|
Isaacs, C. E.,
S. Kashyap,
W. C. Heird, and H. Thormar.
1990.
Antiviral and antibacterial lipids in human milk and infant formula feeds.
Arch. Dis. Child.
65:861-864[Abstract/Free Full Text].
|
| 5.
|
Isaacs, C. E., and H. Thormar.
1991.
The role of milk-derived antimicrobial lipids as antiviral and antibacterial agents.
Adv. Exp. Med. Biol.
310:159-165[Medline].
|
| 5a.
| Isaacs, C. E. Personal communication.
|
| 6.
|
Kabara, J. J.
1978.
Fatty acids and derivatives as antimicrobial agents a review, p. 1-14.
In
J. J. Kabara (ed.), The pharmacological effects of lipids. American Oil Chemists Society, Champaign, Ill.
|
| 7.
|
Lampe, M. F.,
L. M. Ballweber, and W. E. Stamm.
1997.
Susceptibility of Chlamydia trachomatis to chlorhexidine gluconate gel.
Antimicrob. Agents Chemother., submitted for publication.
|
| 8.
|
Lehrer, R. I.,
A. K. Lichtenstein, and T. Ganz.
1993.
Defensins: antimicrobial and cytotoxic peptides of mammalian cells.
Annu. Rev. Immunol.
11:105-128[Medline].
|
| 9.
|
Page, B.,
M. Page, and C. Noel.
1993.
A new fluorometric assay for cytotoxicity measurements in vitro.
Int. J. Oncol.
3:473-476.
|
| 10.
|
Wang, S.-P.,
J. T. Grayston,
C.-C. Kuo,
E. R. Alexander, and K. K. Holmes.
1977.
Serodiagnosis of Chlamydia trachomatis infection with the micro-immunofluorescence test, p. 237-248.
In
D. Hobson, and K. K. Holmes (ed.), Nongonococcal urethritis and related infections. American Society for Microbiology, Washington, D.C.
|
| 11.
|
Yasin, B.,
S. S. Harwig,
R. I. Lehrer, and E. A. Wagar.
1996.
Susceptibility of Chlamydia trachomatis to protegrins and defensins.
Infect. Immun.
64:709-713[Abstract].
|
Antimicrobial Agents and Chemotherapy, May 1998, p. 1239-1244, Vol. 42, No. 5
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Skinner, M. C., Stamm, W. E., Lampe, M. L.
(2009). Chlamydia trachomatis Laboratory Strains versus Recent Clinical Isolates: Implications for Routine Microbicide Testing. Antimicrob. Agents Chemother.
53: 1482-1489
[Abstract]
[Full Text]
-
Sater, A. A. A., Ojcius, D. M., Meyer, M. P.
(2008). Susceptibility of Chlamydia trachomatis to the Excipient Hydroxyethyl Cellulose: pH and Concentration Dependence of Antimicrobial Activity. Antimicrob. Agents Chemother.
52: 2660-2662
[Abstract]
[Full Text]
-
Moncla, B. J., Pryke, K., Isaacs, C. E.
(2008). Killing of Neisseria gonorrhoeae, Streptococcus agalactiae (Group B Streptococcus), Haemophilus ducreyi, and Vaginal Lactobacillus by 3-O-Octyl-sn-Glycerol. Antimicrob. Agents Chemother.
52: 1577-1579
[Abstract]
[Full Text]
-
Isaacs, C. E., Rohan, L., Xu, W., Jia, J. H., Mietzner, T., Hillier, S.
(2006). Inactivation of Herpes Simplex Virus Clinical Isolates by Using a Combination Microbicide. Antimicrob. Agents Chemother.
50: 1063-1066
[Abstract]
[Full Text]
-
Isaacs, C. E.
(2005). Human Milk Inactivates Pathogens Individually, Additively, and Synergistically. J. Nutr.
135: 1286-1288
[Abstract]
[Full Text]
-
Isaacs, C. E., Jia, J. H., Xu, W.
(2004). A Lipid-Peptide Microbicide Inactivates Herpes Simplex Virus. Antimicrob. Agents Chemother.
48: 3182-3184
[Abstract]
[Full Text]
-
Lampe, M. F., Rohan, L. C., Skinner, M. C., Stamm, W. E.
(2004). Susceptibility of Chlamydia trachomatis to Excipients Commonly Used in Topical Microbicide Formulations. Antimicrob. Agents Chemother.
48: 3200-3202
[Abstract]
[Full Text]
-
Ballweber, L. M., Jaynes, J. E., Stamm, W. E., Lampe, M. F.
(2002). In Vitro Microbicidal Activities of Cecropin Peptides D2A21 and D4E1 and Gel Formulations Containing 0.1 to 2% D2A21 against Chlamydia trachomatis. Antimicrob. Agents Chemother.
46: 34-41
[Abstract]
[Full Text]